{
    "Rank": 322,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT01943695",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "15-178"
                },
                "Organization": {
                    "OrgFullName": "Memorial Sloan Kettering Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer",
                "OfficialTitle": "Optimal Timing Trial: Randomized Trial of Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "March 2023",
                "OverallStatus": "Active, not recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "January 2013"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 2024",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "August 2024",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "July 31, 2013",
                "StudyFirstSubmitQCDate": "September 12, 2013",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 17, 2013",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "March 3, 2023",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "March 6, 2023",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Sponsor"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Memorial Sloan Kettering Cancer Center",
                    "LeadSponsorClass": "OTHER"
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "The purpose of this study is to compare the effects of aerobic exercise training during and after chemotherapy for women who have recently been diagnosed with early-stage breast cancer.\n\nThe participant will be instructed to self-report the session information to ExOnc staff at or before their next scheduled visit. If the participant's next scheduled visit is greater than 72 hours following an unsupervised session, ExOnc staff may reach out to the participant to retrieve the session information. Unsupervised session details will be source documented by ExOnc staff."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Breast Cancer",
                        "Exercise",
                        "Chemotherapy",
                        "15-178"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Supportive Care",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "144",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Aerobic Training During Chemotherapy",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training an intensity of at 55% to 100% of the individually determined exercise capacity VO2peak), concurrent with chemotherapy. VO2peak will be determined by the CPET performed at baseline. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Behavioral: Aerobic Training"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Aerobic Training After Chemotherapy",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "The ultimate goal is for participants to complete approximately 3 exercise sessions week of non-linear aerobic training at an intensity 55% to 100% of the individually determined exercise capacity (VO2peak), after the completion of chemotherapy. VO2peak will be determined by the CPET performed at midpoint, or pre-surgery for neoadjuvant patients. For patients receiving adjuvant therapy, (except those who have additional surgery after chemotherapy), the aerobic training intervention must begin within 2 weeks of the patient's midpoint CPET. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, the aerobic training intervention will begin within approximately 6 weeks of surgery, per the discretion of the treating physician. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Behavioral: Aerobic Training"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Continuous Aerobic Training",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "The ultimate goal is for participants to complete 3 exercise sessions week of non-linear aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), during and after chemotherapy. For patients receiving adjuvant therapy (except those who have additional surgery after chemotherapy), VO2peak will be determined by the CPETs performed at baseline and midpoint. For patients receiving neoadjuvant or adjuvant therapy and have additional surgery after chemotherapy, VO2peak will be determined by the CPETs or at baseline, pre- surgery, and post-surgery. The weekly exercise will be achieved via 3 individual aerobic training sessions ranging from approximately 20-45 min/session. All sessions are required to be supervised unless otherwise specified by EP discretion.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Behavioral: Aerobic Training"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "General Physical Activity Group",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, consultation with a staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to record type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress, and answer questions.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Behavioral: Educational Information",
                                    "Behavioral: Supervised Home Based Training"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Behavioral",
                            "InterventionName": "Aerobic Training",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Aerobic Training After Chemotherapy",
                                    "Aerobic Training During Chemotherapy",
                                    "Continuous Aerobic Training"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "exercise, breast cancer, therapy."
                                ]
                            }
                        },
                        {
                            "InterventionType": "Behavioral",
                            "InterventionName": "Educational Information",
                            "InterventionDescription": "Subjects will be given material regarding cancer and it's impact.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "General Physical Activity Group"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Behavioral",
                            "InterventionName": "Supervised Home Based Training",
                            "InterventionDescription": "Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "General Physical Activity Group"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Change in VO2 peak (functional capacity)",
                            "PrimaryOutcomeDescription": "To determine the optimal timing of aerobic activity, relative to an attention-control group, on exercise capacity in a breast cancer setting. This will be evaluated using an electronic motorized treadmill test with 12-lead ECG monitoring (Mac\u00ae 5000, GE Healthcare) performed by certified exercise physiologists.",
                            "PrimaryOutcomeTimeFrame": "during chemotherapy 3-6 months depending on treatment recommendations"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Quality of Life measured by questionnaire during and after Chemotherapy",
                            "SecondaryOutcomeDescription": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.",
                            "SecondaryOutcomeTimeFrame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Sleeping patterns as measured by questionnaire during and after Chemotherapy",
                            "SecondaryOutcomeDescription": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.",
                            "SecondaryOutcomeTimeFrame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Depression scale during and after Chemotherapy",
                            "SecondaryOutcomeDescription": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.",
                            "SecondaryOutcomeTimeFrame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Physical activity recall during and after Chemotherapy",
                            "SecondaryOutcomeDescription": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.",
                            "SecondaryOutcomeTimeFrame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Skeletal Muscle Function",
                            "SecondaryOutcomeDescription": "To examine the physiological mediators of the exercise training - exercise capacity relationship (e.g., skeletal muscle function as assessed by a muscle biopsy)performed.",
                            "SecondaryOutcomeTimeFrame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nAged 21-80 years\nFemale\nMSK histologically confirmed early-stage operable breast cancer\nScheduled to receive chemotherapy in the neoadjuvant or adjuvant setting\nECOG status of 0 or 1\nPerforming less than 150 minutes of structured moderate-intensity or strenuous intensity exercise per week\n\nIf a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study.\n\na. Women < 50 years old must have a negative pregnancy test (urine HCG or serum \u03b2HCG) within 2 weeks of beginning chemotherapy.\n\nAble to complete an acceptable baseline cardiopulmonary exercise test (CPET), in the absence of high risk ECG findings or other inappropriate response to exercise as determined by the investigator.\n\nAble to achieve an acceptable peak baseline CPET, as defined by any of the following criteria:\n\nAchieving a plateau in oxygen consumption, concurrent with an increase in power output;\nA respiratory exchange ratio \u2265 1.10;\nAttainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted HRmax [HRmax = 220-Age[years]);\nVolitional exhaustion, as measured by a rating of perceived exertion (RPE) \u2265 18 on the BORG scale.\nWillingness to be randomized to one of the study arms\n\nExclusion Criteria:\n\nPresence of any other concurrent, actively treated malignancy\nHistory of any other malignancy treated within the past 3 years (other than non-melanoma skin cancer)\nPresence of metastatic disease\nAny of the following contraindications to cardiopulmonary exercise testing:\nAcute myocardial infarction within 3-5 days of any planned study procedures)\nUnstable angina\nUncontrolled arrhythmia causing symptoms or hemodynamic compromise;\nRecurrent syncope\nActive endocarditis\nAcute myocarditis or pericarditis\nSymptomatic severe aortic stenosis\nUncontrolled heart failure\nAcute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures;\nThrombosis of lower extremities\nSuspected dissecting aneurysm\nUncontrolled asthma\nPulmonary edema\nRespiratory failure\nAcute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis) or\nRoom air desaturation at rest \u2264 85%\nMental impairment leading to inability to cooperate.\nAny other condition or intercurrent illness that, in the opinion of the investigator, makes the participant a poor candidate for the trial",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "21 Years",
                "MaximumAge": "80 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Jessica Scott, PhD",
                            "OverallOfficialAffiliation": "Memorial Sloan Kettering Cancer Center",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Memorial Sloan Kettering Cancer Center",
                            "LocationCity": "New York",
                            "LocationState": "New York",
                            "LocationZip": "10065",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "SeeAlsoLinkList": {
                    "SeeAlsoLink": [
                        {
                            "SeeAlsoLinkLabel": "Memorial Sloan Kettering Cancer Center",
                            "SeeAlsoLinkURL": "https://www.mskcc.org/"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}